Non-Mass Enhancements on DCE-MRI: Development and Validation of a Radiomics-Based Signature for Breast Cancer Diagnoses.

Autor:	Li Y; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Yang ZL; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Lv WZ; Department of Artificial Intelligence, Julei Technology Company, Wuhan, China., Qin YJ; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Tang CL; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Yan X; Scientific Marketing, Siemens Healthcare Ltd., Shanghai, China., Guo YH; Magnetic Resonance (MR) Collaboration, Siemens Healthcare, Guangzhou, China., Xia LM; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Ai T; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Sep 22; Vol. 11, pp. 738330. Date of Electronic Publication: 2021 Sep 22 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.738330
Abstrakt:	Purpose: We aimed to assess the additional value of a radiomics-based signature for distinguishing between benign and malignant non-mass enhancement lesions (NMEs) on dynamic contrast-enhanced breast magnetic resonance imaging (breast DCE-MRI). Methods: In this retrospective study, 232 patients with 247 histopathologically confirmed NMEs (malignant: 191; benign: 56) were enrolled from December 2017 to October 2020 as a primary cohort to develop the discriminative models. Radiomic features were extracted from one post-contrast phase (around 90s after contrast injection) of breast DCE-MRI images. The least absolute shrinkage and selection operator (LASSO) regression model was adapted to select features and construct the radiomics-based signature. Based on clinical and routine MR features, radiomics features, and combined information, three discriminative models were built using multivariable logistic regression analyses. In addition, an independent cohort of 72 patients with 72 NMEs (malignant: 50; benign: 22) was collected from November 2020 to April 2021 for the validation of the three discriminative models. Finally, the combined model was assessed using nomogram and decision curve analyses. Results: The routine MR model with two selected features of the time-intensity curve (TIC) type and MR-reported axillary lymph node (ALN) status showed a high sensitivity of 0.942 (95%CI, 0.906 - 0.974) and low specificity of 0.589 (95%CI, 0.464 - 0.714). The radiomics model with six selected features was significantly correlated with malignancy (P<0.001 for both primary and validation cohorts). Finally, the individual combined model, which contained factors including TIC types and radiomics signatures, showed good discrimination, with an acceptable sensitivity of 0.869 (95%CI, 0.816 to 0.916), improved specificity of 0.839 (95%CI, 0.750 to 0.929). The nomogram was applied to the validation cohort, reaching good discrimination, with a sensitivity of 0.820 (95%CI, 0.700 to 0.920), specificity of 0.864 (95%CI,0.682 to 1.000). The combined model was clinically helpful, as demonstrated by decision curve analysis. Conclusions: Our study added radiomics signatures into a conventional clinical model and developed a radiomics nomogram including radiomics signatures and TIC types. This radiomics model could be used to differentiate benign from malignant NMEs in patients with suspicious lesions on breast MRI. Competing Interests: Author XY and YG were employed by the Siemens Healthcare company. WL was employed by Julei Technology Company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Li, Yang, Lv, Qin, Tang, Yan, Guo, Xia and Ai.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu